Summit Therapeutics (NASDAQ: SMMT) BLA filing and GSK trial pact detailed

Rhea-AI Filing Summary

Summit Therapeutics Inc. reported that as of December 31, 2025, its preliminary unaudited balance of cash, cash equivalents, and short-term investments was approximately $710 million, noting this figure may change once year-end closing procedures are completed.

The company disclosed that it has submitted a Biologics License Application to the U.S. Food and Drug Administration seeking approval for ivonescimab, in combination with chemotherapy, for second line or later treatment of patients with epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous non-small cell lung cancer.

Summit also announced a clinical trial collaboration with GSK plc to evaluate ivonescimab with GSK’s investigational B7-H3 targeting antibody-drug conjugate, risvutatug rezetecan (GSK’227), in multiple solid tumors, including small cell lung cancer. In addition, Summit intends to present at the 44th Annual J.P. Morgan Healthcare Conference, with investor presentation slides and related press releases furnished as exhibits.

Positive

• Regulatory milestone for ivonescimab: Submission of a Biologics License Application to the U.S. FDA for ivonescimab plus chemotherapy in second line or later EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer establishes a clear path toward potential approval in a defined lung cancer population.
• Strategic collaboration with GSK: A new clinical trial collaboration with GSK plc to test ivonescimab with GSK’s investigational B7-H3 targeting ADC, risvutatug rezetecan (GSK’227), across multiple solid tumors, including small cell lung cancer, expands ivonescimab’s development into additional indications with a major pharmaceutical partner.
• Strong preliminary liquidity: Preliminary unaudited cash, cash equivalents, and short-term investments of approximately $710 million as of December 31, 2025 suggest substantial resources to support ongoing clinical, regulatory, and potential commercialization activities once year-end figures are finalized.

Negative

• None.

Insights

Biopharma & Capital Markets Analyst

Summit highlights strong liquidity, an FDA BLA submission for ivonescimab, and a new GSK trial collaboration.

Summit Therapeutics Inc. indicates preliminary unaudited cash, cash equivalents, and short-term investments of about $710 million as of December 31, 2025, pending completion of financial closing. This level of liquidity provides context for funding clinical development and potential commercialization activities once year-end figures are finalized.

The company has submitted a Biologics License Application to the U.S. Food and Drug Administration for ivonescimab plus chemotherapy as second line or later treatment for epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous non-small cell lung cancer. A BLA submission is a key regulatory milestone that, if accepted and ultimately approved, could support commercial use of the regimen in this defined patient group.

Summit also announced a clinical trial collaboration with GSK plc to evaluate ivonescimab with GSK’s investigational B7-H3 targeting antibody-drug conjugate, risvutatug rezetecan (GSK’227), across multiple solid tumors, including small cell lung cancer. This collaboration connects ivonescimab with an external oncology portfolio and broadens its evaluation into additional tumor types, while the company’s participation in the 44th Annual J.P. Morgan Healthcare Conference and related investor materials helps communicate these developments to the market.

0001599298FALSE00015992982026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 12, 2026

Summit Therapeutics Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware			001-36866			37-1979717
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
601 Brickell Key Drive, Suite 1000, Miami, FL						33131
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (305) 203-2034

Not applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class			Trading Symbol(s)			Name of Each Exchange on Which Registered
Common stock, $0.01 par value per share			SMMT			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Conditions.

As of December 31, 2025, the preliminary unaudited balance of cash, cash equivalents, and short-term investments of Summit Therapeutics Inc. (the “Company”) was approximately $710 million. This amount is preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company’s consolidated financial statements for the year ended December 31, 2025.

In accordance with General Instruction B.2 of Form 8-K, the information set forth under Item 2.02 and in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, the Company intends to present at the 44th Annual J.P. Morgan Healthcare Conference. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01 as if fully set forth herein.

On January 12, 2026, the Company issued a press release announcing the submission of a Biologics License Application to U.S. Food and Drug Administration seeking approval for ivonescimab in combination with chemotherapy in second line or later treatment of patients with epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous non-small cell lung cancer. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

On January 12, 2026, the Company issued a press release announcing a clinical trial collaboration with GSK plc (“GSK”) to evaluate ivonescimab in combination with GSK’s risvutatug rezetecan (also known as GSK’227), GSK’s novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC). A copy of the press release is attached as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information set forth under Item 7.01 and in Exhibits 99.1, 99.2 and 99.3 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number			Description
99.1			Investor Presentation Slides made available on January 12, 2026
99.2			Press release, dated January 12, 2026
99.3			Press release, dated January 12, 2026
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

			SUMMIT THERAPEUTICS INC.
Date: January 12, 2026			By:			/s/ Manmeet S. Soni
						Chief Operating Officer, Chief Financial Officer and Director
						(Principal Financial Officer)

FAQ

What cash position did Summit Therapeutics (SMMT) report as of December 31, 2025?

As of December 31, 2025, Summit Therapeutics Inc. reported a preliminary unaudited balance of approximately $710 million in cash, cash equivalents, and short-term investments, subject to completion of financial closing procedures.

What regulatory step did Summit Therapeutics (SMMT) take for ivonescimab?

Summit Therapeutics Inc. submitted a Biologics License Application to the U.S. Food and Drug Administration seeking approval for ivonescimab in combination with chemotherapy for second line or later treatment of patients with epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous non-small cell lung cancer.

What is the new collaboration between Summit Therapeutics (SMMT) and GSK?

Summit Therapeutics Inc. announced a clinical trial collaboration with GSK plc to evaluate ivonescimab in combination with GSK’s investigational B7-H3 targeting antibody-drug conjugate, risvutatug rezetecan (GSK’227), across multiple solid tumor settings, including small cell lung cancer.

Which cancer indications are targeted in Summit Therapeutics’ BLA for ivonescimab?

The Biologics License Application seeks approval for ivonescimab plus chemotherapy in second line or later treatment of patients with epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous non-small cell lung cancer.

What major conference is Summit Therapeutics (SMMT) presenting at?

On January 12, 2026, Summit Therapeutics Inc. intends to present at the 44th Annual J.P. Morgan Healthcare Conference, with investor presentation slides furnished as an exhibit.

Are Summit Therapeutics’ cash figures in this report final?

No. The approximately $710 million in cash, cash equivalents, and short-term investments as of December 31, 2025 is described as preliminary and unaudited and may differ materially once financial closing procedures are completed.